Most mitochondrial treatment should begin with a simpler question: what is interfering with cellular energy production? Nutrient deficiency, metabolic dysfunction, poor sleep, inflammation, medication effects, impaired oxygen delivery and underlying disease may all create mitochondrial stress.

Advanced therapies become more meaningful after those factors have been considered. The goal is not to find the strongest mitochondrial treatment. It is to determine which part of mitochondrial biology may actually need support.

Four Different Ways to Target Mitochondrial Function

The easiest way to understand advanced mitochondrial treatment is to separate the interventions according to what they are attempting to influence.

SS-31 / Elamipretide: Targeting the Mitochondrial Membrane

SS-31—also known as elamipretide—is fundamentally different from a mitochondrial vitamin or metabolic substrate. It is a mitochondria-targeting tetrapeptide that localizes to the inner mitochondrial membrane and interacts with cardiolipin.

Cardiolipin is an unusual phospholipid concentrated within the inner mitochondrial membrane. It helps organize mitochondrial cristae and supports proteins involved in electron transport and oxidative phosphorylation.

Current research suggests that the SS-31–cardiolipin interaction can influence mitochondrial membrane organization, respiratory-chain protein assembly, bioenergetics and oxidative stress. This membrane-targeting mechanism is one reason SS-31 has attracted interest across muscle, cardiovascular, renal and ocular mitochondrial research.

Why Is Barth Syndrome Important to the SS-31 Story?

Barth syndrome is especially relevant because it involves abnormal cardiolipin remodeling. The disease therefore provides a particularly direct connection between cardiolipin biology, mitochondrial membrane dysfunction and elamipretide's proposed target.

In 2025, the FDA granted accelerated approval to Forzinity based on improvement in knee extensor muscle strength considered reasonably likely to predict clinical benefit. Confirmatory study requirements remain part of that accelerated-approval pathway.

MOTS-c: Mitochondria as a Signaling Organ

MOTS-c represents an entirely different mitochondrial concept.

Rather than being a molecule designed primarily to stabilize the mitochondrial membrane, MOTS-c is a mitochondrial-derived peptide encoded within mitochondrial DNA. Research suggests that it participates in metabolic signaling and cellular adaptation to stress.

Under cellular stress, MOTS-c has been reported to influence nuclear gene expression. Experimental research has connected the peptide with glucose metabolism, insulin sensitivity, skeletal-muscle metabolism and exercise adaptation.

Human research also shows that endogenous mitochondrial-derived peptides respond to exercise. However, much of the therapeutic excitement surrounding administering MOTS-c itself still comes from preclinical research rather than established clinical treatment trials.

SS-31 vs. MOTS-c: They Are Not Interchangeable

NAD+: Supporting Cellular Redox and Energy Metabolism

NAD+ is not a mitochondrial peptide. It is an essential cellular coenzyme involved in oxidation-reduction reactions throughout metabolism.

The NAD+/NADH system helps transfer electrons during the processing of carbohydrates, fats and other fuels. NAD+ also serves as a substrate for enzymes involved in cellular signaling, DNA repair and stress responses.

This has created considerable interest in NAD+-raising strategies, particularly nicotinamide riboside (NR), nicotinamide mononucleotide (NMN) and intravenous NAD+.

Human trials show that oral NR and NMN can increase NAD-related metabolites, demonstrating biochemical target engagement. But improvements in energy, metabolic function, physical performance and other clinical outcomes have been inconsistent.

Red & Near-Infrared Light: Photobiomodulation

Photobiomodulation uses specific wavelengths of red or near-infrared light to influence cellular signaling. One proposed mitochondrial target is cytochrome c oxidase, a component of the respiratory chain.

Research suggests photobiomodulation can influence mitochondrial bioenergetics, reactive oxygen species signaling, nitric oxide pathways and downstream inflammatory responses.

Clinical evidence is considerably broader for some pain, tissue-repair and rehabilitation applications than it is for treating a generalized diagnosis of “mitochondrial dysfunction.” Wavelength, dose, tissue penetration and treatment protocol matter.

Exercise May Be the Most Important Mitochondrial Signal

Exercise is not merely a way of burning calories. It creates a controlled energetic challenge that can stimulate mitochondrial adaptation.

Depending upon intensity and training status, exercise can influence mitochondrial biogenesis, oxidative capacity, insulin sensitivity, vascular function and skeletal-muscle metabolism.

Interestingly, human studies have also demonstrated that exercise changes endogenous mitochondrial-derived peptide signaling, including MOTS-c-related responses.

Heat, Cold and Mitochondrial Adaptation

Heat and cold exposure are sometimes described as mitochondrial therapies because they impose controlled physiologic stress.

Heat exposure can activate heat-shock and cellular stress-response pathways. Cold exposure can influence sympathetic signaling, thermogenesis and brown adipose tissue metabolism.

These are better viewed as adaptive physiologic stimuli than as direct treatments for a specific mitochondrial defect.

What About Hyperbaric Oxygen Therapy?

Hyperbaric oxygen therapy increases dissolved oxygen exposure and has established medical indications unrelated to generalized mitochondrial dysfunction.

There is research interest in its effects on oxidative signaling, vascular biology, tissue repair and mitochondrial adaptation. However, the fact that mitochondria use oxygen does not mean that more oxygen automatically improves mitochondrial function.

HBOT should therefore remain a condition-specific medical intervention, not a universal mitochondrial treatment.

Can Mitochondrial Testing Tell Us Which Advanced Therapy Will Work?

Not yet.

This is one of the most important distinctions in the entire mitochondrial evaluation.

Markers such as GDF-15, lactate/pyruvate, CK, free and total carnitine, acylcarnitines and organic acids can contribute different information about mitochondrial and metabolic function.

An abnormal result may strengthen the evidence that cellular-energy metabolism deserves attention. It does not automatically select a peptide.

Who Should Consider Advanced Mitochondrial Therapy?

The threshold should be higher than simply having fatigue or wanting more energy.

Advanced Therapy Should Still Have a Measurement Strategy

Whether the intervention is nutritional, physiologic or investigational, treatment becomes much more useful when there is a defined baseline.

When a laboratory abnormality was present initially, repeating that marker may provide useful objective information. But the most meaningful endpoint remains whether the patient's function actually improves.

The Future of Mitochondrial Medicine Is More Targeted

The emerging mitochondrial field is moving away from the idea that mitochondrial dysfunction should simply be treated with a larger supplement cocktail.

SS-31 illustrates the possibility of targeting mitochondrial structure. MOTS-c illustrates mitochondria acting as signaling organelles. NAD+ strategies target cellular redox metabolism. Exercise and photobiomodulation attempt to influence adaptive mitochondrial biology.

These approaches may eventually allow mitochondrial therapy to become increasingly individualized—but the evidence is not equally mature for each intervention.

Frequently Asked Questions About Mitochondrial Peptides